Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.

Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.

<h4>Background</h4>Tyrosine kinases are attractive targets for pancreatic cancer therapy because several are over-expressed, including PDGFRalpha/beta, FAK, Src and Lyn. A critical role of mast cells in the development of pancreatic cancer has also been reported. Masitinib is a tyrosine...

Full description

Bibliographic Details
Main Authors: Martine Humbert, Nathalie Castéran, Sébastien Letard, Katia Hanssens, Juan Iovanna, Pascal Finetti, François Bertucci, Thomas Bader, Colin D Mansfield, Alain Moussy, Olivier Hermine, Patrice Dubreuil
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-03-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20209107/pdf/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20209107/pdf/?tool=EBI

Similar Items